



National  
Comprehensive  
Cancer  
Network®

**NCCN.org**

Fred Hutchinson Cancer  
Research Center/  
Seattle Cancer Care Alliance

Huntsman Cancer Institute  
at the U. of Utah

UCSF Helen Diller Family  
Comprehensive Cancer Center

Stanford Cancer Institute

City of Hope Comprehensive  
Cancer Center

The University of Texas  
MD Anderson Cancer Center

UNMC Eppley Cancer  
Center at The Nebraska  
Medical Center

Siteman Cancer Center  
at Barnes-Jewish Hospital  
and Washington U.  
School of Medicine

St. Jude Children's  
Research Hospital/  
U. of Tennessee  
Cancer Institute

Robert H. Lurie  
Comprehensive Cancer  
Center of Northwestern U.

The Ohio State University  
Comprehensive Cancer Center -  
James Cancer Hospital and  
Solove Research Institute

Vanderbilt-Ingram  
Cancer Center

U. of Alabama  
at Birmingham  
Comprehensive  
Cancer Center

H. Lee Moffitt Cancer  
Center & Research Institute

Roswell Park  
Cancer Institute

U. of Michigan  
Comprehensive  
Cancer Center

Dana-Farber/Brigham and  
Women's Cancer Center  
Massachusetts General Hospital  
Cancer Center

Memorial Sloan-Kettering  
Cancer Center

Fox Chase Cancer Center

The Sidney Kimmel  
Comprehensive Cancer  
Center at Johns Hopkins


Duke Cancer Institute



National  
Comprehensive  
Cancer  
Network®

## What is NCCN?

*On behalf of patients, NCCN seeks to positively influence and improve decisions and policies that impact the access to, availability of, and delivery of appropriate and effective cancer care.*




# NCCN Guidelines™

- Standard for Clinical Policy in Oncology in United States
- 46 Multidisciplinary Panels with 25-30 experts per panel (Volunteer time and expertise)
- Widely available free of charge worldwide to all including Medical, Radiation, and Surgical Oncologists; Oncology Nurses; Pharmacists, etc.
- Over 100 Updated (continually) Individual Guidelines
- Basis for insurance coverage policy and quality evaluation



# NCCN.org


## Unique Visitors October 2010 – October 2011






# NCCN Guidelines™ User Survey

## Clinicians Using NCCN Guidelines for Patient Care Decision-Making and As a Reference Tool (n= 1,687)





## NCCN Guidelines®

### NCCN Influence on Payers

- “By far the most influential guidelines for oncology treatment decisions are those published by the National Comprehensive Cancer Network, used by 86.5% of MCOs.”
  - The 2010-2011 Genentech Oncology Trend Report



- “Reimbursement Intelligence...polled 55 insurers and found that...ninety percent of those insurers looked to the NCCN Compendium for guidance, with most covering an indication ranked 2B or above.”
- *Managed Care Magazine*, September 2011

# NCCN Biomarker Compendium™ in Development

- To ensure access to appropriate testing as recommended by NCCN Guidelines
- Identify the utility of a specific test to screen, diagnose, monitor, or provide predictive or prognostic information
- Provide information about specific tests
- Discriminate between clinically useful tests and those that are not yet clinically indicated

# NCCN Guidelines Panels Existing Recommendations for Testing

Currently more than 800 biomarker recommendations in NCCN Guidelines:

- Determine risk of disease (BRCA-1/BRCA-2)
- Screening (PSA for prostate)
- Diagnostic (BCR/ABL in CML)
- Prognostic (CA 19-9 in pancreas)
- Predictive (ER/PR status in breast)
- Risk of toxicity (UGT1A1\*28 allele for irinotecan)
- Response/disease monitoring (AFP; HCG in testicular)

# NCCN Biomarker Compendium™

Specific Indication	Molecular Abnormality	Test Purpose	Methodology	NCCN Level of Evidence	Specimen Types	NCCN Recommendation
Breast Cancer: DCIS Newly DX Stage I-IV	ER expression	Prognostic Predictive	IHC	2A	FFPE tumor tissue	Positive result predicts responsiveness to hormone therapy in invasive disease and possible prevention in DCIS
CML: Chronic Phase Adult CML	BCR-ABL t(9;22) translocation	diagnosis	FISH	2A	Bone marrow, peripheral blood	Philadelphia chromosome (BCR-ABL, t(9;22) translocation is diagnostic for CML. If bone marrow is not feasible....



## NCCN Policy Summits

### NCCN Molecular Testing Work Group

- To provide guidance regarding challenges of molecular testing to healthcare providers and other stakeholders, NCCN convened a Work Group in May 2011, comprised of thought leaders from NCCN Member Institutions and other organizations. These multidisciplinary thought leaders represented providers (physicians and pathologists), patients, manufacturers, payers, and government.
- The Work Group focused on the following challenge areas:
  - Regulatory Policy
  - Reimbursement Issues and Coverage Policy
  - Clinical and Practical Issues



National  
Comprehensive  
Cancer  
Network®

**NCCN.org**

Fred Hutchinson Cancer  
Research Center/  
Seattle Cancer Care Alliance

Huntsman Cancer Institute  
at the U. of Utah

UCSF Helen Diller Family  
Comprehensive Cancer Center

Stanford Cancer Institute

City of Hope Comprehensive  
Cancer Center

The University of Texas  
MD Anderson Cancer Center

UNMC Eppley Cancer  
Center at The Nebraska  
Medical Center

Siteman Cancer Center  
at Barnes-Jewish Hospital  
and Washington U.  
School of Medicine

St. Jude Children's  
Research Hospital/  
U. of Tennessee  
Cancer Institute

Robert H. Lurie  
Comprehensive Cancer  
Center of Northwestern U.

The Ohio State University  
Comprehensive Cancer Center -  
James Cancer Hospital and  
Solove Research Institute

Vanderbilt-Ingram  
Cancer Center

U. of Alabama  
at Birmingham  
Comprehensive  
Cancer Center

H. Lee Moffitt Cancer  
Center & Research Institute

Roswell Park  
Cancer Institute

U. of Michigan  
Comprehensive  
Cancer Center

Dana-Farber/Brigham and  
Women's Cancer Center  
Massachusetts General Hospital  
Cancer Center

Memorial Sloan-Kettering  
Cancer Center

Fox Chase Cancer Center

The Sidney Kimmel  
Comprehensive Cancer  
Center at Johns Hopkins

Duke Cancer Institute